Depression, violence and cortisol awakening response: a 3-year longitudinal study in adolescents.


Journal

Psychological medicine
ISSN: 1469-8978
Titre abrégé: Psychol Med
Pays: England
ID NLM: 1254142

Informations de publication

Date de publication:
04 2019
Historique:
pubmed: 18 7 2018
medline: 1 5 2020
entrez: 18 7 2018
Statut: ppublish

Résumé

Despite evidence of links between depression and violent outcomes, potential moderators of this association remain unknown. The current study tested whether a biological marker, cortisol, moderated this association in a longitudinal sample of adolescents. Participants were 358 Dutch adolescents (205 boys) with a mean age of 15 years at the first measurement. Depressive symptoms, the cortisol awakening response (CAR) and violent outcomes were measured annually across 3 years. The CAR was assessed by two measures: waking cortisol activity (CAR area under the curve ground) and waking cortisol reactivity (CAR area under the curve increase). Within-individual regression models were adopted to test the interaction effects between depressive symptoms and CAR on violent outcomes, which accounted for all time-invariant factors such as genetic factors and early environments. We additionally adjusted for time-varying factors including alcohol drinking, substance use and stressful life events. In this community sample, 24% of adolescents perpetrated violent behaviours over 3 years. We found that CAR moderated the effects of depressive symptoms on adolescent violent outcomes (βs ranged from -0.12 to -0.28). In particular, when the CAR was low, depressive symptoms were positively associated with violent outcomes in within-individual models, whereas the associations were reversed when the CAR was high. Our findings suggest that the CAR should be investigated further as a potential biological marker for violence in adolescents with high levels of depressive symptoms.

Sections du résumé

BACKGROUND
Despite evidence of links between depression and violent outcomes, potential moderators of this association remain unknown. The current study tested whether a biological marker, cortisol, moderated this association in a longitudinal sample of adolescents.
METHODS
Participants were 358 Dutch adolescents (205 boys) with a mean age of 15 years at the first measurement. Depressive symptoms, the cortisol awakening response (CAR) and violent outcomes were measured annually across 3 years. The CAR was assessed by two measures: waking cortisol activity (CAR area under the curve ground) and waking cortisol reactivity (CAR area under the curve increase). Within-individual regression models were adopted to test the interaction effects between depressive symptoms and CAR on violent outcomes, which accounted for all time-invariant factors such as genetic factors and early environments. We additionally adjusted for time-varying factors including alcohol drinking, substance use and stressful life events.
RESULTS
In this community sample, 24% of adolescents perpetrated violent behaviours over 3 years. We found that CAR moderated the effects of depressive symptoms on adolescent violent outcomes (βs ranged from -0.12 to -0.28). In particular, when the CAR was low, depressive symptoms were positively associated with violent outcomes in within-individual models, whereas the associations were reversed when the CAR was high.
CONCLUSIONS
Our findings suggest that the CAR should be investigated further as a potential biological marker for violence in adolescents with high levels of depressive symptoms.

Identifiants

pubmed: 30012227
pii: S0033291718001654
doi: 10.1017/S0033291718001654
pmc: PMC6240346
mid: EMS78976
doi:

Substances chimiques

Biomarkers 0
Hydrocortisone WI4X0X7BPJ

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

997-1004

Subventions

Organisme : Wellcome Trust
ID : 202836
Pays : United Kingdom
Organisme : Wellcome Trust
ID : 202836/Z/16/Z
Pays : United Kingdom

Références

Psychoneuroendocrinology. 2003 Oct;28(7):916-31
pubmed: 12892658
J Abnorm Child Psychol. 1991 Aug;19(4):469-78
pubmed: 1757712
Psychoneuroendocrinology. 2013 Nov;38(11):2485-92
pubmed: 23768972
J Abnorm Child Psychol. 1993 Oct;21(5):469-80
pubmed: 8294648
J Abnorm Child Psychol. 2002 Aug;30(4):311-26
pubmed: 12108763
Lancet. 2012 Jun 23;379(9834):2373-82
pubmed: 22726518
Child Dev. 2009 May-Jun;80(3):907-20
pubmed: 19489911
Psychoneuroendocrinology. 2015 Jun;56:88-99
pubmed: 25813123
Biol Psychol. 2009 Mar;80(3):265-78
pubmed: 19022335
J Consult Clin Psychol. 2011 Aug;79(4):458-69
pubmed: 21787049
Biol Psychiatry. 2008 Oct 1;64(7):599-606
pubmed: 18620338
Psychoneuroendocrinology. 2013 Sep;38(9):1476-83
pubmed: 23312064
Dev Psychobiol. 2012 Jul;54(5):493-502
pubmed: 21953537
Child Dev. 2017 Jan;88(1):27-40
pubmed: 28042897
J Pediatr. 2009 Dec;155(6):904-908.e3
pubmed: 19683724
Soc Psychiatry Psychiatr Epidemiol. 2012 Mar;47(3):487-503
pubmed: 21359532
Psychol Rev. 1993 Oct;100(4):674-701
pubmed: 8255953
JAMA. 2009 Jun 17;301(23):2462-71
pubmed: 19531786
Biomed Res Int. 2013;2013:349530
pubmed: 23841064
J Child Psychol Psychiatry. 2012 Dec;53(12):1233-41
pubmed: 22747770
Psychoneuroendocrinology. 2009 Aug;34(7):1019-28
pubmed: 19278790
Lancet Psychiatry. 2015 Mar;2(3):224-32
pubmed: 26236648
Arch Gen Psychiatry. 2000 Oct;57(10):979-86
pubmed: 11015816
Int J Epidemiol. 2014 Feb;43(1):264-9
pubmed: 24366487
J Am Acad Child Adolesc Psychiatry. 2015 Jan;54(1):37-44.e2
pubmed: 25524788
Am J Epidemiol. 2006 Dec 15;164(12):1199-208
pubmed: 17032695
Lancet. 2012 Mar 17;379(9820):1056-67
pubmed: 22305766
Dev Psychopathol. 2005 Winter;17(1):167-84
pubmed: 15971765
Stress. 2004 Mar;7(1):29-37
pubmed: 15204030
Psychosom Med. 2013 Nov-Dec;75(9):832-40
pubmed: 24184845
J Am Acad Child Adolesc Psychiatry. 1994 Oct;33(8):1174-84
pubmed: 7982868
Biol Psychiatry. 2007 Feb 1;61(3):405-11
pubmed: 16950214
Psychoneuroendocrinology. 2007 Jan;32(1):80-6
pubmed: 17127010
Arch Gen Psychiatry. 2001 Mar;58(3):297-302
pubmed: 11231837
Psychoneuroendocrinology. 2000 Oct;25(7):707-20
pubmed: 10938450
Psychoneuroendocrinology. 2009 Feb;34(2):163-71
pubmed: 19095358
Biol Psychiatry. 2014 Jan 1;75(1):9-17
pubmed: 23786983
Dev Psychopathol. 1999 Winter;11(1):59-84
pubmed: 10208356
Biol Psychol. 2013 Apr;93(1):132-7
pubmed: 23348558
Life Sci. 1997;61(26):2539-49
pubmed: 9416776
Child Dev. 2008 Sep-Oct;79(5):1185-229
pubmed: 18826521
Dev Psychopathol. 2015 Aug;27(3):885-99
pubmed: 25058564
Biol Psychiatry. 2004 Mar 1;55(5):546-52
pubmed: 15023584
Psychoneuroendocrinology. 2015 May;55:146-53
pubmed: 25765756
J Am Acad Child Adolesc Psychiatry. 2003 Sep;42(9):1101-7
pubmed: 12960710
Psychol Med. 2015 Jul;45(10):2171-9
pubmed: 25765219
Soc Psychiatry Psychiatr Epidemiol. 1999 Dec;34(12):657-63
pubmed: 10703276
Behav Res Methods. 2009 Aug;41(3):924-36
pubmed: 19587209
Dev Psychol. 2016 Dec;52(12):1994-2009
pubmed: 27893244
J Am Acad Child Adolesc Psychiatry. 2017 Aug;56(8):652-658.e1
pubmed: 28735694

Auteurs

Rongqin Yu (R)

Department of Psychiatry,University of Oxford,Oxford,UK.

Susan Branje (S)

Department of Youth and Family,Utrecht University,Utrecht,The Netherlands.

Wim Meeus (W)

Department of Youth and Family,Utrecht University,Utrecht,The Netherlands.

Philip Cowen (P)

Department of Psychiatry,University of Oxford,Oxford,UK.

Seena Fazel (S)

Department of Psychiatry,University of Oxford,Oxford,UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH